BACKGROUND AND AIM: Nonalcoholic fatty liver disease (NAFLD), circulating insulin-like growth factor-1 (IGF-1), and IGF-1/IGF-binding protein-3 (IGFBP-3) concentrations are associated with adiposity and insulin resistance. We aimed to determine whether serum IGF-1, IGFBP-3, and IGF-1/IGFBP-3 are associated with presence or severity of NAFLD independent of potential confounding. METHODS: We performed a cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey, 1988–1994, a representative sample of the United States adult population. Among participants who had a fasting blood draw and ultrasound examination, we excluded those with missing data, viral hepatitis, iron overload, excessive alcohol intake, pregnancy, or taking glucose-lowering therapy, yielding 4172 adults for this analysis. RESULTS: In logistic regression analyses adjusted for age, gender, and race/ethnicity, higher IGF-1 and IGF-1/IGFBP-3 quartiles were associated with lower likelihood of NAFLD and lower grade steatosis. These associations became non-significant when further adjusted for adiposity (body mass index, waist circumference) with the exception of the association between IGF-1/IGFBP-3 and severity of NAFLD which remained significant after adjustment for homeostasis model assessment for insulin resistance (HOMA-IR) (odds ratio [95% CI]: Q3: 0.71 [0.53–0.96], Q4: 0.62 [0.43–0.89]) and adiposity (Q4: 0.67 [0.47–0.96]). Full adjustment (age, gender, race/ethnicity, adiposity, HOMA-IR, A1C%) further attenuated associations between IGF-1 or IGF-1/IGFBP-3 and liver fat such that they were no longer significant. CONCLUSIONS: Adiposity explains much of the observed association between IGF-1 or IGF-1/IGFBP-3 and liver fat. These findings do not support a direct role for the growth hormone-IGF-1/IGFBP-3 axis in the pathophysiology of NAFLD.
BACKGROUND AND AIM: Nonalcoholic fatty liver disease (NAFLD), circulating insulin-like growth factor-1 (IGF-1), and IGF-1/IGF-binding protein-3 (IGFBP-3) concentrations are associated with adiposity and insulin resistance. We aimed to determine whether serum IGF-1, IGFBP-3, and IGF-1/IGFBP-3 are associated with presence or severity of NAFLD independent of potential confounding. METHODS: We performed a cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey, 1988–1994, a representative sample of the United States adult population. Among participants who had a fasting blood draw and ultrasound examination, we excluded those with missing data, viral hepatitis, iron overload, excessive alcohol intake, pregnancy, or taking glucose-lowering therapy, yielding 4172 adults for this analysis. RESULTS: In logistic regression analyses adjusted for age, gender, and race/ethnicity, higher IGF-1 and IGF-1/IGFBP-3 quartiles were associated with lower likelihood of NAFLD and lower grade steatosis. These associations became non-significant when further adjusted for adiposity (body mass index, waist circumference) with the exception of the association between IGF-1/IGFBP-3 and severity of NAFLD which remained significant after adjustment for homeostasis model assessment for insulin resistance (HOMA-IR) (odds ratio [95% CI]: Q3: 0.71 [0.53–0.96], Q4: 0.62 [0.43–0.89]) and adiposity (Q4: 0.67 [0.47–0.96]). Full adjustment (age, gender, race/ethnicity, adiposity, HOMA-IR, A1C%) further attenuated associations between IGF-1 or IGF-1/IGFBP-3 and liver fat such that they were no longer significant. CONCLUSIONS: Adiposity explains much of the observed association between IGF-1 or IGF-1/IGFBP-3 and liver fat. These findings do not support a direct role for the growth hormone-IGF-1/IGFBP-3 axis in the pathophysiology of NAFLD.
Authors: T Krusenstjerna-Hafstrøm; B F Clasen; N Møller; N Jessen; S B Pedersen; J S Christiansen; J O L Jørgensen Journal: J Clin Endocrinol Metab Date: 2011-05-25 Impact factor: 5.958
Authors: Y Liu; C A Fernandez; C Smith; W Yang; C Cheng; J C Panetta; N Kornegay; C Liu; L B Ramsey; S E Karol; L J Janke; E C Larsen; N Winick; W L Carroll; M L Loh; E A Raetz; S P Hunger; M Devidas; J J Yang; C G Mullighan; J Zhang; W E Evans; S Jeha; C-H Pui; M V Relling Journal: Clin Pharmacol Ther Date: 2017-04-04 Impact factor: 6.875
Authors: Laura E Dichtel; Kathleen E Corey; Melanie S Haines; Mark L Chicote; Allison Kimball; Caitlin Colling; Tracey G Simon; Michelle T Long; Jad Husseini; Miriam A Bredella; Karen K Miller Journal: J Clin Endocrinol Metab Date: 2022-08-18 Impact factor: 6.134
Authors: Jose Cordoba-Chacon; Neena Majumdar; Edward O List; Alberto Diaz-Ruiz; Stuart J Frank; Anna Manzano; Ramon Bartrons; Michelle Puchowicz; John J Kopchick; Rhonda D Kineman Journal: Diabetes Date: 2015-05-26 Impact factor: 9.461
Authors: Laura E Dichtel; Kathleen E Corey; Joseph Misdraji; Miriam A Bredella; Melanie Schorr; Stephanie A Osganian; Brian J Young; Joshua C Sung; Karen K Miller Journal: Clin Transl Gastroenterol Date: 2017-01-26 Impact factor: 4.488
Authors: Andre Sarmento-Cabral; Mercedes Del Rio-Moreno; Mari C Vazquez-Borrego; Mariyah Mahmood; Elena Gutierrez-Casado; Natalie Pelke; Grace Guzman; Papasani V Subbaiah; Jose Cordoba-Chacon; Shoshana Yakar; Rhonda D Kineman Journal: J Endocrinol Date: 2021-01 Impact factor: 4.286
Authors: Takara L Stanley; Lindsay T Fourman; Isabel Zheng; Colin M McClure; Meghan N Feldpausch; Martin Torriani; Kathleen E Corey; Raymond T Chung; Hang Lee; David E Kleiner; Colleen M Hadigan; Steven K Grinspoon Journal: J Clin Endocrinol Metab Date: 2021-01-23 Impact factor: 5.958
Authors: Eleonora Poggiogalle; Carla Lubrano; Lucio Gnessi; Stefania Mariani; Andrea Lenzi; Lorenzo Maria Donini Journal: PLoS One Date: 2016-01-07 Impact factor: 3.240